Featured Publications

Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis.

Lu LL, Das J, Grace PS, Fortune SM, Restrepo BI, Alter G, J. Infect. Dis. 2020 Feb

Publisher Correction: IFN-?-independent immune markers of Mycobacterium tuberculosis exposure.

Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH, McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR, Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G, Nat. Med. 2019 Jun

IFN-?-independent immune markers of Mycobacterium tuberculosis exposure.

Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH, McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR, Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G, Nat. Med. 2019 06 25 6 977-987

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P, Am. J. Respir. Crit. Care Med. 2019 Mar 199 5 564-571

An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

McLean MR, Lu LL, Kent SJ, Chung AW, Front Immunol 2019 10 2846

Introduction: Physician-Scientists in the Evolving Landscape of Biomedical Research.

Lu LL, Kwon DS, Barczak AK, J. Infect. Dis. 2018 Aug 218 suppl_1 S1-S2

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.

Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ, Nat. Med. 2018 02 24 2 130-143

Beyond binding: antibody effector functions in infectious diseases.

Lu LL, Suscovich TJ, Fortune SM, Alter G, Nat. Rev. Immunol. 2018 Jan 18 1 46-61

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG, NPJ Vaccines 2018 3 34

A Functional Role for Antibodies in Tuberculosis.

Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G, Cell 2016 Oct 167 2 433-443.e14